For Lyme disease sufferers, could AI listen when doctors won’t? ‘On the outside they look perfectly fine, on the inside they are dying,’ says the father of a patient with Lyme diseaseA new research effort is using patient stories, DNA analyses and more to better understand the controversial disease.

Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites ‘growing skepticism’ in downgrade Company shares extend declines after dropping on third-quarter earnings last weekSangamo is developing innovative gene-editing programs for many devastating diseases, but a J.P. Morgan analyst called it a ‘show-me story from here.’

How your iPhone could save your life A new study says an iPhone app identifies potentially fatal heart attacks with near-accuracy of an ECGA new study says an iPhone app identifies potentially fatal heart attacks with near-accuracy of an ECG.

This doctor’s response to the Tree of Life shooting is an example for us all It’s critically important to play one’s position and lead despite fear and dangerIt’s critically important to play one’s position and lead despite fear and danger.

An expensive new medication is finally available for her rare disease — but she’s been fighting for two years to get it Annie Wilson hopes that the therapy, Spinraza, will halt her progressive diseaseMore and more rare-disease medications have been approved in recent years, but a tangle of complications can keep promising but expensive therapies out of reach for patients.

Michelle Obama had IVF treatment — what is it and what does it cost? About 10% of women between 15 and 44 years old have difficulty getting or staying pregnantAbout 10% of women between 15 and 44 years old have difficulty getting or staying pregnant.

This unusual program cuts you a check when you shop around for a cheaper medical procedure DirectPath Rewards gives patients an overview of their options by cost and gives them a cut if they choose a cheaper oneOne woman’s wallet is more than $300 fatter because of it.

CVS expects Aetna deal to close by ThanksgivingCVS Health Corp. executives gave investors a window into its strategy after closing the acquisition of health insurer Aetna Inc., with an eye on becoming a one-stop shop for patients. The CVS-Aetna merger -- which brings together the giant drugstore chain and pharmacy-benefit manager with the No. 3 health insurer -- needs the approval from five more states to complete the deal.

This is why access to health care means more than just covering pre-existing conditions Providing access to health care is more complex than this one areaPoliticians need to look at other barriers to health-care access too, writes J.B. Silvers, a former CEO of a health plan.

How do you know if you have a ‘Top Doctor’ or an incompetent, unethical one? Some ways you can avoid a medical catastropheThe real story behind those Yelp stars and ‘Best Doctor’ lists — and when to be suspicious.

Powerful new opioid 500 times stronger than morphine approved in U.S. in spite of outcry FDA said questions about new opioids were valid, even as it approved the new productCritics worried about putting such a potent and addictive medication on the market in the midst of the U.S.’s opioid crisis.

The bigger message behind Amgen’s decision to slash cost of its Repatha cholesterol drug Drug companies look to haggle less and sell more, and that could cost Express Scripts, CVS Health and UnitedHealthDrug companies look to haggle less and sell more, and that could cost Express Scripts, CVS Health and UnitedHealth.

This experimental Alzheimer’s disease drug seemed promising — before the latest results left many unsure Critics said that the results were ‘thin, unconvincing,’ and that a small patient population limited ‘drawing any sort of firm conclusion’A big question hanging over the drug was not resolved — but it did get more complicated.

Bio-bonds: A new way to invest in the medical miracles of the future Karen Petrou is pushing for a funding mechanism that could attract a new crop of investorsKaren Petrou is pushing for a funding mechanism that could attract a new crop of investors.

In 'high risk gambit,' Amgen slashes price of underused cholesterol drugAmgen Inc. announced this week that it will cut the price of its cholesterol-lowering medication Repatha by 60% to $5,850 a year. The company will make identical lower-priced options available starting immediately, and will keep offering Repatha at its original price in the meantime, expecting to discontinue that price tag by the end of 2020 or before. The price change is geared at reducing patient out-of-pocket costs, particularly for those on Medicare, Amgen Chief Executive Robert Bradway said, citing an estimate that three-quarters of those on Medicare who are prescribed Repatha or a drug like it don't fill their prescriptions. The move follows a decision by Regeneron and Sanofi [S: SNY] earlier this year to offer on a rival product, Praluent, for health insurers and middlemen called pharmacy-benefit managers. Amgen also said that the price reduction reflects the company's "support for the goal of President Trump and his Administration to lower the price of drugs for U.S. consumers." Regeneron and Praluent are intended for patients whose cholesterol levels haven't been reduced sufficiently by lifestyle changes or statins, but they have not sold well, in large part due to high price tags. RBC Capital Markets analyst Kennen MacKay described the move as a "high risk gambit" aimed at increasing Repatha sales. "Overall, we see this move as a positive for the U.S. healthcare system and cardiovascular disease/dyslipidemia patients, however it remains unclear whether this price/volume sacrifice will net favorably, and we anticipate investors will view this pricing strategy as somewhat of a commercial 'show me' story before growing more constructive on Repatha and the class," he said. Amgen shares rose 1% in Thursday premarket trade. Shares have dropped 2.7% over the last three months, compared with a 6.7% drop in the Dow Jones Industrial Average and a 3.3% drop in the Dow Jones Industrial Average .

New pain drug from Pfizer and Eli Lilly shows promise as opioid alternative Safety results will likely be a particular focus, in this trial and results forthcoming in 2019The drug, from Pfizer and Eli Lilly, has had a checkered history but shows promise in osteoarthritis pain.

As powerful new opioid nears FDA approval, critics ask if U.S. is stoking its drug crisis The product consists of an opioid that is 500 times stronger than morphine but drugmaker defends its needAs a new medication intended for quick pain relief nears a U.S. approval decision, critics worry about putting another strong opioid on the market amid a devastating opioid crisis.

As opioid crisis raged, Insys pushed higher doses of addictive drug and pushed salespeople to ‘own’ doctors Concerning sales tactics involving a potent opioid medication were highlighted in a new Senate committee report‘It is much easier to take an existing patient and double their units,’ one sales manager wrote, referring to patients as ‘low hanging fruit.’

This one easy change can boost your retirement savings as much as $108,000 The connection between your health and your retirement fundsA noted retirement analyst and a family physician have a surprising way to beef up your 401(k).

Marijuana stocks to watch: Meet the drugmaker making cannabis-based medicines for autism, cancer and more GW Pharma’s lead therapy, Epidiolex, is the U.S.’s first cannabis-derived drugDrugmakers commonly make their medicines synthetically — think a lab, not a greenhouse. But because its medications employ cannabinoids, the U.K.-based GW Pharma also grows it own cannabis plants.

This elephant can teach us a lot about retirement and aging A look at how the Smithsonian’s National Zoo cares for elderly animalsOlder zoo animals are free from worries of Social Security or being sent to a nursing home.

University of Southern California to pay $215 million to settle sex-abuse case Women allege widespread misconduct by former campus gynecologist George TyndallThe University of Southern California agrees to pay $215 million to settle a federal lawsuit brought against it by women who have accused a former campus gynecologist, George Tyndall, of sexual abuse and misconduct.

When women can’t access abortion, some take drastic measures A new study looks at what happens in states with only a few abortion clinicsA new study looks at what happens in states with only a few abortion clinics.

Why does opioid dependence vary so dramatically by U.S. state? Nearly every state is affected by the opioid crisis, some more than othersNearly every state is affected by the opioid crisis, some more than others.

Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early Shares soar in public debut, after IPO prices well above expected range to value company at $1.6 billionThe startup’s cancer tests help match patients with the right treatments. It also has even bigger ambitions: to use its tests to find cancer recurrences, and even for early detection of cancers.

Neovasc shares soar 24% on news of positive data from first U.S. patient to use device to treat anginaNeovasc Inc. shares soared more than 24% in premarket trade Wednesday, after the company announced positive data from the first U.S. patient to be implanted with a device to treat refractory angina. The Vancouver-based medical device company said its Neovasc Reducer produced positive data in a 12-week follow-up on the patient, who was able to walk several miles without symptoms and greatly reduce his use of nitroglycerin. Prior to using the device, the patient could walk only two blocks before experiencing angina and used nitroglycerin two to three times a week. The device has already achieved positive results in European studies, according to Chief Executive Fred Colen. Refractory angina affects 600,000 to 1.8 million Americans with up to 100,000 new cases emerging every year. Neovasc shares have fallen 96% in 2018 through Tuesday, while the S&P 500 has gained 9%.

How changing the way we pay for health care could save money and lives Cutting out the middlemen, Walmart, General Motors and other companies are experimenting with new models for health coverageWalmart, General Motors and Whole Foods, in what may be a wave of the future, are contracting directly with health providers.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.